Category Archives: Biotechnology

Auris Medical Holding Ltd (EARS) is around the middle of the Biotechnology industry according to InvestorsObserver. EARS received an overall rating of 52, which means that it scores higher than 52 percent of all stocks. Auris Medical Holding Ltd also achieved a score of 59 in the Biotechnology industry, putting it above 59 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 52 means the stock is more attractive than 52 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Auris Medical Holding Ltd (EARS) stock is trading at $2.70 as of 9:56 AM on Tuesday, Dec 15, a rise of $0.02, or 0.75% from the previous closing price of $2.68. The stock has traded between $2.62 and $2.87 so far today. Volume today is light. So far 137,427 shares have traded compared to average volume of 12,164,180 shares.

Click Here to get the full Stock Score Report on Auris Medical Holding Ltd (EARS) Stock.

Follow this link:
Where Does Auris Medical Holding Ltd (EARS) Stock Fall in the Biotechnology Field? - InvestorsObserver

Thats the philosophy of Felix Paul Joe and preferably the biggest explanation one can have for his unflinching crusade in the field of biotech research. Felix founded GeneX India Bioscience Pvt. Ltd. in 2004 but, the journey before it prepared him for everything that came next.

After earning a Masters in Life Science and Post Graduate Diploma in Business Administration from the University of Madras and Madras Productivity Council, Felix was all set to create his own path in biotechnology. But, revolution is a way paved stone by stone. Before realizing his passion and dream to become an entrepreneur, Felix completed a nine-year run in different biotech companies. As a National Sales & Product Manager, he embarked on a journey that shaped his understanding of what the industry is and what it needs.

He attended a plethora of application training on varied subjects like molecular biology, cellular microscopy, interphase chromosome profiling and Proteomics. His learnings from these teachings formed a crucial part of his ventures growth model in the later years. He also completed exclusive product training and lab sessions at many international labs and forums during his days as a manager. Working with many Centres for Excellence labs across India, Felix perceived the need for a bridge between the Indian and global standards.

In 2004, when Felix established GeneX India Bioscience, the company only started as a distributor of cell culture products. Molecular biology and biotechnology were then added to widen the spectrum. Today, the company focusses in the fields of bio-science research institutes, molecular diagnostic labs, biopharmaceutical R&D, biotech contract research and development centres.

Over the years, the organization created a line of products and solutions, namely Cell Biology, Real-Time PCR, Epigenetics, Next Generation Sequencing and Protein Biology. The private company is a full-fledged service provider for cell biology, flowcytometry and proteomics. As envisioned by Felix, GeneX also acts as a middleman nurturing quality products, scientific and technical support between biotech solution providers in Europe, USA, UK and Indian researchers who work across the relevant fields.

GeneX India has an experienced team of 33 scientifically-qualified professionals who possess the capability to market, conduct workshops, seminars. They cumulatively provide solutions to scientists and research scholars, helping them complete their research. The team works in constant collaboration mode to ensure a zero-defect product and service range. The stringent quality standard and client-centric approach have made the enterprise synonymous to the word biotech all across the world.

Following this unprecedented rise, GeneX India has been recognized for its efforts via major accolades like the Biotech Excellence and the APJ Abdul Kalam Excellence Award. The CEO magazine also noted GeneX as one of the 25 fastest growing biotechnology companies in India recently. Moreover, Felix himself has been the recipient of multiple national and international awards such as the Mahatma Gandhi Samman at the House of Commons, UK.

Even during the COVID pandemic, Felix and his company have been dedicated to aiding ICMR approved testing labs and kit manufacturers. Vaccine research labs and producers are being helped in complete sync too.

As the future entails, Felix is now set on scaling the firm to global benchmarks and giving Indian research the world stage it deserves. A plan to support the bioprocess and vaccine development has been put in place as well. He also aims to produce affordable molecular diagnostic kits using the latest technology like the CRISPR Cas9 Genome editing tool. A Contract Research Lab that acts as a high-end core facility with its primary focus on Genomics and DNA sequencing for molecular diagnostics is also in the works. The end goal is to provide services to biotech researchers and in turn, become a parallel economic solution provider for the high throughput, time-bound turnkey biotech projects and diagnostic labs.

A reputable part of the significant science congresses across the country, Felix has always had the vision to create a sustainable future for the world. He has a strong conviction that the firms business model should make a profound and positive impact on the lives of all the researchers it touches. His every step has been towards building his own pathway that treads towards this purpose.

Go here to see the original:
Cell Biology, Molecular Biology, Biotechnology And The Man Who Is Connecting It All: Felix Paul Joe - Outlook India

A rating of 98 puts Oncolytics Biotech, Inc. (ONCY) near the top of the Biotechnology industry according to InvestorsObserver. Oncolytics Biotech, Inc.'s score of 98 means it scores higher than 98% of stocks in the industry. Oncolytics Biotech, Inc. also received an overall rating of 83, putting it above 83% of all stocks. Biotechnology is ranked 37 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 83 would rank higher than 83 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Oncolytics Biotech, Inc. (ONCY) stock is trading at $3.91 as of 11:51 AM on Friday, Dec 4, an increase of $0.28, or 7.71% from the previous closing price of $3.63. The stock has traded between $3.63 and $3.95 so far today. Volume today is 1,004,118 compared to average volume of 1,138,833.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

More:
Is Oncolytics Biotech, Inc. (ONCY) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

New Jersey, United States,-

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: An analysis for future growth

Global Nanoparticles in Biotechnology and Pharmaceuticals Market report has added committed areas covering the tendencies of the target crowd and the opposition as of now present on the lookout. Because of the COVID-19 pandemic, numerous organizations have confronted a colossal plunge in their functions and sales. However, the Global Nanoparticles in Biotechnology and Pharmaceuticals market has pushed through this unpleasant market fix and came out with brilliant outcomes. This has pulled in the consideration of large organizations as well as the new companies too, to attempt their hands in one of the steadiest markets.

To comprehend the market elements and mainstays of the Global Nanoparticles in Biotechnology and Pharmaceuticals market, the report helps in unwinding the insider facts behind the consistent development of the market since initiation. Factors, for example, political situation, segments focal points and tendency of target crowd are a portion of the main considerations that either drive the business forward or pull them down.

Request Sample Copy of this Report @ Nanoparticles in Biotechnology and Pharmaceuticals Market Size

In market segmentation by manufacturers, the report covers the following companies-

Why is it important to understand the post-COVID19 Global Nanoparticles in Biotechnology and Pharmaceuticals -market?

The capital inflow and outpouring of the Global Nanoparticles in Biotechnology and Pharmaceuticals -market is consistent in any event, during the progressing pandemic, pushing it as one of the most solid organizations during the ongoing occasions. To measure the market openings, customers can exploit the recommendable activities pointed in the report. These activities are attempted and tried prior to imparting to customers to set aside their time and cash.

How to overcome obstacles for the septennial 2020-2027 using the Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

Presently, going to the main part-outside elements. Porters five powers are the main components to be thought of while moving into new business markets. The customers get the opportunity to use the approaches to plan the field-tested strategies without any preparation for the impending monetary years.

We have faith in our services and the data we share with our esteemed customers. In this way, we have done long periods of examination and top to bottom investigation of the Globalmarket to give out profound bits of knowledge about the Global Nanoparticles in Biotechnology and Pharmaceuticals market. Along these lines, the customers are enabled with the instruments of data (as far as raw numbers are concerned).

The graphs, diagrams and infographics are utilized to speak out about the market drifts that have formed the market. Past patterns uncover the market turbulences and the final results on the markets. Then again, the investigation of latest things uncovered the ways, the organizations must take for shaping themselves to line up with the market.

What type of data is added into the Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

Working corresponding to the market can be troublesome however not with the direction from the Global Nanoparticles in Biotechnology and Pharmaceuticals market report. The report shares the data gathered from the official sites of the administering bodies and the yearly reports of the current market players. Making the report reliable and trustworthy. Thusly, the market can be perceived from its foundations.

To accomplish greatest ROI alongside increasing most extreme lump of the market, the customers can use the information from the Global Nanoparticles in Biotechnology and Pharmaceuticals market report. The report gives step-wise strategies to accomplish for transient objectives. For understanding the drawn out objectives, the report grandstands the advantages of dealing with the partners and the encompassing individuals on the lookout. This will help the business endeavours in coming out with brilliant numbers.

What are the advantages of using Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

The opponents referenced in the report are added for instance purposes and can be changed according to the prerequisites set forward by the customers. Advantages related with Global Nanoparticles in Biotechnology and Pharmaceuticals market report are recorded underneath:

1. Long-term and momentary investigation of the objectives for the customers. 2. In-profundity investigation of the inside and outside elements affecting the organizations development. 3. Exploring the socioeconomics best appropriate for venturing into the new market. 4. Examination of patterns through trials for outlining powerful and proficient strategies. 5. Ways to raise capital for smooth working of the associations business. 6. Working parallel to the market through proper SWOT and PESTLE examinations.

Have Any Query? Ask Our Expert @ Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

About us:

Market Research Blogs is a leading Global Research and Consulting firm servicing over 5000+ customers. Market Research Blogs provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Get More Market Research Report Click @ Market Research Blogs

See more here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Share, Growth, Trends, Outlook, Scope and Forecast to 2027 - The Haitian-Caribbean...

IT has been nearly two decades since the Philippine government approved the sale and cultivation of genetically modified (GM) corn seeds in local farms. The government issued a permit to commercialize Monsanto Philippiness bacillus thuringiensis (Bt) corn variety dubbed YieldGard on December 5, 2002. With this, the Philippines earned the distinction of being the first in Asia to commercialize Bt corn, a variety that enables corn farmers to save on production cost because they will no longer have to extensively use pesticides to kill the corn borera grain pest, particularly of corn.

Bt corn has been largely instrumental in increasing farmers production in the ensuing years following the issuance of the permit to Monsanto. The increment in output allowed the Philippines to become self-sufficient in corn (See, Yellow corn yield achieved 103 percent self-sufficiency last yearPiol, in the BusinessMirror, March 28, 2018). With the help of the biotech product, farmers were able to earn $642 million from 2003 to 2015, according to the International Service for the Acquisition of Agri-biotech Applications.

Its advantages and its potential to boost incomes have encouraged more farmers to plant the variety in recent years. The United States Department of Agricultures Foreign Agricultural Service in Manila noted that areas planted with Bt corn in the Philippines expanded by 26 percent to 834,617 hectares this year (See, Gain report: GE corn areas in PHL continue to expand, in the BusinessMirror, November 30, 2020). The availability of more yellow corna raw material used in manufacturing animal feedshas also supported the growing livestock and poultry industry.

These developments illustrate the benefits of biotechnology as well as its potential to enable the Philippines to develop other products that will allow farmers to diversify to other crops as well as cope with the ill effects of climate change. Currently, Bt corn is the only biotech product that is being planted in the Philippines. The GM varieties of other crops, like eggplant, are in various stages of development.

It is also worth noting that the Bt corn variety that was approved for commercialization in 2002 was made in the United States. The Philippines has yet to develop its own GM crop, and we urge Philippine researchers and scientists to make biotech products that are tailor fit to local conditions. Government must support these efforts by putting more money in the research initiatives of our local scientists or introduce policies, such as incentives, that will encourage the private sector to partner with them.

The recent successive typhoons that struck the Philippines should serve as a stark reminder of the increasing difficulties being faced by Filipino farmers and the pressing need for government to look for more sustainable means of ensuring food security. We welcome the Department of Agricultures (DA) pronouncement that it will optimize the use of biotechnology and other science-based solutions to increase farm output from limited farmlands and fishing grounds.

We urge Congress to support the DAs initiatives by passing the proposed Modern Biotechnology Act and by increasing the budget for agricultural research and development. Fully supported, our own scientists can harness the power of modern biotechnology.

Read more:
Reaping the promise of biotechnology - Business Mirror

A rating of 80 puts Cellectar Biosciences Inc (CLRB) near the top of the Biotechnology industry according to InvestorsObserver. Cellectar Biosciences Inc's score of 80 means it scores higher than 80% of stocks in the industry. Cellectar Biosciences Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 35 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cellectar Biosciences Inc (CLRB) stock is trading at $2.29 as of 2:18 PM on Thursday, Dec 3, an increase of $0.34, or 17.18% from the previous closing price of $1.95. The stock has traded between $1.95 and $2.40 so far today. Volume today is high. So far 8,826,004 shares have traded compared to average volume of 928,593 shares.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Read this article:
Is Cellectar Biosciences Inc (CLRB) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver